MedTrace Logo

A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

NCT03443453 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-02-23

No results posted yet for this study

Summary

This is a single-Center, Randomised, 4-Period, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Effect of Food on Pharmacokinetics following Single Doses of MIV-711 Capsule and Tablet Formulations in Healthy Volunteers

Conditions

  • Healthy

Interventions

DRUG

MIV-711

MIV-711 administered as tablets and capsules at four occasions

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Allen Hunt · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2018-02-17
Completion
2018-02-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03443453 on ClinicalTrials.gov